Healthcare - Biotechnology - NASDAQ - US
$ 6.175
-10.6 %
$ 1.73 B
Market Cap
-4.23
P/E
CASH FLOW STATEMENT
-288 M
OPERATING CASH FLOW
-10.2 M
INVESTING CASH FLOW
140 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Recursion Pharmaceuticals, Inc.
| Net Income | -328 M |
| Depreciation & Amortization | 24.4 M |
| Capital Expenditures | -12 M |
| Stock-Based Compensation | 53.5 M |
| Change in Working Capital | -50.3 M |
| Others | -36.6 M |
| Free Cash Flow | -300 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (328.1) | (239.5) | (186.5) | (87.0) | (61.9) |
| Depreciation & Amortization | 24.4 | 11.8 | 8.4 | 4.4 | 2.5 |
| Deferred Income Tax | 0 | 0 | 0.8 | 1.8 | 1.1 |
| Stock Based Compensation | 53.5 | 27.9 | 14.8 | 4.3 | 1.4 |
| Other Operating Activities | 12.6 | 11.4 | 4.1 | 0.3 | (0.5) |
| Change in Working Capital | (50.3) | 104.9 | (0.3) | 30.8 | 0.4 |
| Cash From Operations | (287.8) | (83.5) | (158.6) | (45.4) | (57.0) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (12.0) | (37.4) | (39.8) | (6.7) | (3.9) |
| Other Items | 1.7 | 230.6 | (231.9) | (2.0) | 0 |
| Cash From Investing Activities | (10.2) | 193.2 | (271.7) | (8.7) | (3.9) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (0.8) | 90 K | (12.8) | 6.3 | 0.7 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 12.8 | 10.7 | 8.4 | 239.8 | 119.7 |
| Cash From Financing Activities | 140.1 | 154.3 | 458.5 | 246.1 | 120.4 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (157.7) | 263.8 | 28.2 | 192.0 | 59.5 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (300.3) | (120.9) | (198.4) | (52.1) | (61.0) |